PL2559689T3 - Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowego - Google Patents
Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowegoInfo
- Publication number
- PL2559689T3 PL2559689T3 PL12185448T PL12185448T PL2559689T3 PL 2559689 T3 PL2559689 T3 PL 2559689T3 PL 12185448 T PL12185448 T PL 12185448T PL 12185448 T PL12185448 T PL 12185448T PL 2559689 T3 PL2559689 T3 PL 2559689T3
- Authority
- PL
- Poland
- Prior art keywords
- oxadiazol
- fluorophenyl
- benzoic acid
- preparation process
- crystalline forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84732606P | 2006-09-25 | 2006-09-25 | |
| EP12185448.3A EP2559689B1 (en) | 2006-09-25 | 2007-09-24 | Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid |
| EP07838770.1A EP2076501B8 (en) | 2006-09-25 | 2007-09-24 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2559689T3 true PL2559689T3 (pl) | 2018-04-30 |
Family
ID=39123850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12185448T PL2559689T3 (pl) | 2006-09-25 | 2007-09-24 | Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowego |
| PL07838770T PL2076501T3 (pl) | 2006-09-25 | 2007-09-24 | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07838770T PL2076501T3 (pl) | 2006-09-25 | 2007-09-24 | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
Country Status (29)
| Country | Link |
|---|---|
| US (10) | US7863456B2 (ja) |
| EP (2) | EP2559689B1 (ja) |
| JP (6) | JP5714228B2 (ja) |
| KR (1) | KR101430144B1 (ja) |
| CN (3) | CN101541770A (ja) |
| AR (2) | AR062963A1 (ja) |
| AU (1) | AU2007300542B2 (ja) |
| BR (1) | BRPI0717107A2 (ja) |
| CA (1) | CA2663574C (ja) |
| CL (1) | CL2007002743A1 (ja) |
| DK (1) | DK2076501T3 (ja) |
| ES (2) | ES2655338T3 (ja) |
| HK (1) | HK1207070A1 (ja) |
| HU (1) | HUE028503T2 (ja) |
| IL (1) | IL197717A (ja) |
| LT (1) | LTC2076501I2 (ja) |
| MX (2) | MX2009003160A (ja) |
| MY (1) | MY191209A (ja) |
| NO (1) | NO341858B1 (ja) |
| NZ (1) | NZ575795A (ja) |
| PE (3) | PE20120768A1 (ja) |
| PL (2) | PL2559689T3 (ja) |
| PT (1) | PT2076501E (ja) |
| SG (2) | SG10201609581TA (ja) |
| SI (1) | SI2076501T1 (ja) |
| TW (2) | TWI452038B (ja) |
| UA (1) | UA99600C2 (ja) |
| WO (1) | WO2008039431A2 (ja) |
| ZA (1) | ZA200901949B (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA84420C2 (ru) | 2003-04-11 | 2008-10-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК |
| JP5800451B2 (ja) * | 2005-04-08 | 2015-10-28 | ピーティーシー セラピューティクス，インコーポレーテッド | ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物 |
| JP5367563B2 (ja) | 2006-03-30 | 2013-12-11 | ピーティーシー セラピューティクス，インコーポレーテッド | ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療 |
| PL2559689T3 (pl) | 2006-09-25 | 2018-04-30 | Ptc Therapeutics, Inc. | Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowego |
| PL2073805T3 (pl) | 2006-10-12 | 2015-08-31 | Ptc Therapeutics Inc | Sposoby dawkowania 1,2,3-oksadiazolu aktywnego po podaniu doustnym w terapii supresyjnej mutacji nonsensownej |
| KR101512548B1 (ko) | 2010-03-12 | 2015-04-15 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
| EP2981597A1 (en) | 2013-04-03 | 2016-02-10 | GFO Oil LLC | Methods and systems for generating aldehydes from organic seed oils |
| SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
| CA3174516A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| KR101703137B1 (ko) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
| CN114213356A (zh) | 2015-03-10 | 2022-03-22 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
| JP2018513153A (ja) | 2015-04-24 | 2018-05-24 | オメロス コーポレーション | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 |
| WO2017075312A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| WO2017181193A2 (en) * | 2016-04-15 | 2017-10-19 | The Uab Research Foundation | Methods and compounds for stimulating read-through of premature termination codons |
| EP3512516A1 (en) * | 2016-09-13 | 2019-07-24 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| SG11202003081WA (en) | 2017-10-11 | 2020-05-28 | Aurigene Discovery Tech Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| WO2019087087A1 (en) | 2017-11-03 | 2019-05-09 | Aurigene Discovery Technologies Limited | Dual inhibitors of tim-3 and pd-1 pathways |
| EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
| JP7339900B2 (ja) * | 2020-02-26 | 2023-09-06 | 新 井上 | 視野異常診断方法、視野異常診断装置 |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| CN118178408A (zh) * | 2024-03-22 | 2024-06-14 | 核工业总医院 | Ptc124在制备治疗血小板无力症的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW264475B (ja) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1638776A (zh) * | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| WO2004001010A2 (en) * | 2002-06-21 | 2003-12-31 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US6889231B1 (en) * | 2002-08-01 | 2005-05-03 | Oracle International Corporation | Asynchronous information sharing system |
| TW200812986A (en) * | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| UA84420C2 (ru) * | 2003-04-11 | 2008-10-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК |
| US20050075375A1 (en) * | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| EP3067053A1 (en) * | 2004-10-13 | 2016-09-14 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| CA2588994A1 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| JP5800451B2 (ja) | 2005-04-08 | 2015-10-28 | ピーティーシー セラピューティクス，インコーポレーテッド | ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物 |
| CA2842625C (en) * | 2006-09-08 | 2016-07-12 | Ptc Therapeutics, Inc. | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
| PL2559689T3 (pl) * | 2006-09-25 | 2018-04-30 | Ptc Therapeutics, Inc. | Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowego |
| CA3174516A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
-
2007
- 2007-09-24 PL PL12185448T patent/PL2559689T3/pl unknown
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/ko active IP Right Grant
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/es active IP Right Grant
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/pt not_active Application Discontinuation
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/ja active Active
- 2007-09-24 UA UAA200904012A patent/UA99600C2/ru unknown
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 AR ARP070104212A patent/AR062963A1/es not_active Application Discontinuation
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/zh active Pending
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/zh active Active
- 2007-09-24 PL PL07838770T patent/PL2076501T3/pl unknown
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/en active Active
- 2007-09-24 SI SI200731750A patent/SI2076501T1/sl unknown
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 MX MX2011007120A patent/MX344418B/es unknown
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/en active Active
- 2007-09-24 CA CA2663574A patent/CA2663574C/en active Active
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/xx unknown
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/es active Active
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/zh active Pending
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/da active
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/es unknown
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/es active Active
- 2007-09-24 PT PT78387701T patent/PT2076501E/pt unknown
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/en active Application Filing
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/es not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/zh active
- 2007-09-26 TW TW103104823A patent/TWI496775B/zh active
-
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/no unknown
-
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
-
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
-
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
-
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/ja active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/xx unknown
-
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/lt unknown
-
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/ja active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/es unknown
-
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
-
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/ja not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en active Active
-
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/ja active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en not_active Abandoned
-
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2559689T3 (pl) | Sposób wytwarzania postaci krystalicznych kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]benzoesowego | |
| MX2009002439A (es) | Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. | |
| IL192242A0 (en) | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides | |
| IL210261A (en) | 5– (phenyl permitted) s–– triazolo [5,1– a] pyridine – 2 μl of affluent carboxylic acid carboxylic acid for use as drugs | |
| HK1158627A1 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h- pyrrole derivatives as acid secretion inhibitors | |
| IL183700A0 (en) | Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts | |
| PL1896425T3 (pl) | Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy | |
| WO2009037538A3 (en) | Process for the preparation of lamivudine form i | |
| WO2008065123A3 (en) | Polymorphic forms of deferasirox ( icl670a) | |
| IL186294A0 (en) | A process for the preparation of phenyltetrazole compounds | |
| IL199239A0 (en) | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6- | |
| HK1144192A1 (en) | Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester (r)-3--345- 1-[222] | |
| ZA200809554B (en) | 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides | |
| CL2007003011A1 (es) | Forma salina de compuestos de benzotienilo sustituidos; procedimiento de preparacion; sal mono-colina de acido (e)-{(5-cloro-benzo[b]tiofen-3-il)-[2-(3,4-difluorfenil)-vinilcarbamoil]-metil}-metil-fosfinico. | |
| IL210923A0 (en) | A crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4,-triazol-3-yl)pyridine | |
| IL206613A0 (en) | Process for the production of 4-(substituted phenyl) hexahydropyrido[2,1-c][1,4]oxazin-6-one | |
| IL210924A0 (en) | A new crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |